Genotype Factors and Mineral Status for the Expression of Prostate Cancer among Whites and Blacks Races
Main Article Content
Abstract
Prostate cancer are more in number nowadays its third most frequently occurred cancer in the world. So prevalence of PC is necessary to reduce risk, mortality and morbidity. It has so many pre-disposing factors in that genetical variation are most important because genetical variation can be caused by may be due to chemical agents, hereditary, X -rays and etc… some essential vitamin can causes the prostate cancer and insulin induced factor are also involved .But in another way vitamin can cure the cancer at early stages of cancer.selenium is the one trace element induced the prostate cancer.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. https://doi.org/10.3322/caac.21660 (2021). (1)
II. Culp, M. B., Soerjomataram, I., Efstathiou, J. A., Bray, F. & Jemal, A. Recent global patterns in prostate cancer incidence and mortality rates. Eur. Urol. 77, 38–52 (2020). (2)
III. Dai, C., Heemers, H. & Sharifi, N. Androgen signaling in prostate cancer. Cold Spring Harb. Perspect. Med. 7, a03045 (2017)(3)
IV. Scott M. Lippman and others, Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT), JNCI: Journal of the National Cancer Institute, Volume 97, Issue 2, 19 January 2005, Pages 94–102, https://doi.org/10.1093/jnci/dji009 (4)
V. Edward Giovannucci and others, Intake of Carotenoids and Retino in Relation to Risk of Prostate Cancer, JNCI: Journal of the National Cancer Institute, Volume 87, Issue 23, 6 December 1995, Pages 1767–1776, https://doi.org/10.1093/jnci/87.23.1767(5)
VI. Chan JM, Giovannucci EL. Dairy products, calcium, and vitamin D and risk of prostate cancer. Epidemiologic reviews. 2001 Jan 1;23(1):87-92.(6)
VII. Wu I, Modlin CS. Disparities in prostate cancer in African American men: what primary care physicians can do. Cleve Clin J Med. 2012 May 1;79(5):313-20. (7)
VIII. Okobia MN, Zmuda JM, Ferrell RE, Patrick AL, Bunker CH. Chromosome 8q24 variants are associated with prostate cancer risk in a high risk population of African ancestry. Prostate 2011; 71:1054–1063.(8)
IX. Powell I, Sakr W, Weiss L, et al. Prostate cancer is biologically more CLEVELAND CLINIC JOURNAL OF MEDICINE VOLUME 79 • NUMBER 5 MAY 2012 319 Wu and Modlin aggressive among African Americans than Caucasian men under age 70: hypothesis supported by autopsy and SEER data. Program and abstracts from the American Urological Association 95th Annual Meeting; April 29–May 4, 2000: Atlanta, GA.(9)
X. Kyle C, Ewing T, Wu XC, et al. Statewide analysis of serum prostate specific antigen levels in Louisiana men without prostate cancer. J La State Med Soc 2004; 156:319–323. 38.(10)
XI. Vijayakumar S, Winter K, Sause W, et al. Prostate-specific antigen levels are higher in African-American than in white patients in a multicenter registration study: results of RTOG 94-12. Int J Radiat Oncol Biol Phys 1998; 40:17–25 (11)
XII. Rebbeck TR, Haas GP: Temporal trends and racial disparities in global prostate cancer prevalence. Can J Urol 21 (5): 7496-506, 2014. (12)
XIII. Bray F, Ferlay J, Soerjomataram I, et al.: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68 (6): 394-424, 2018. (13)
XIV. American Cancer Society: Cancer Facts and Figures 2022. American Cancer Society, 2022. Available onlineExit Disclaimer. Last accessed October 7, 2022. (14)
XV. Amundadottir LT, Sulem P, Gudmundsson J, et al. A common variant associated with prostate cancer in European and African populations. Nat Genet 2006;38:652–8.(15)
XVI. Powell IJ. Epidemiology and pathophysiology of prostate cancer in African-American men. J Urol 2007; 177:444–9. (16)
XVII. Agalliu I, Salinas CA, Stanford JL. Use of statins and risk of prostate cancer. 2008 Am J Epidemiol. In Press.(17)
XVIII. Gudmundsson J, Sulem P, Manolescu A, et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24.
a. Nat Genet2007;39:631–7.(18)
XIX. Robbins C, Torres JB, Hooker S, Bonilla C, Hernandez W, Candreva A, Ahaghotu C, Kittles R, Carpten J. Confirmation study of prostate cancer risk variants at 8q24 in African Americans identifies a novel risk locus. Genome research. 2007 Dec 1;17(12):1717-22. (19)
XX. Chang BL, Cramer SD, Wiklund F, Isaacs SD, Stevens VL, Sun J, Smith S, Pruett K, Romero LM, Wiley KE, Kim ST. Fine mapping association study and functional analysis implicate a SNP in MSMB at 10q11 as a causal variant for prostate cancer risk. Human molecular genetics. 2009 Apr 1;18(7):1368-75. (20)
XXI. Grönberg H, Isaacs SD, Smith JR, Carpten JD, Bova GS, Freije D, Xu J, Meyers DA, Collins FS, Trent JM, Walsh PC. Characteristics of prostate cancer in families potentially linked to the hereditary prostate cancer 1 (HPC1) locus. Jama. 1997 Oct 15;278(15):1251-5. (21)
XXII. Rennert H, Zeigler-Johnson CM, Addya K, Finley MJ, Walker AH, Spangler E, Leonard DG, Wein A, Malkowicz SB, Rebbeck TR. Association of susceptibility alleles in ELAC2/HPC2, RNASEL/HPC1, and MSR1 with prostate cancer severity in European American and African American men. Cancer Epidemiology Biomarkers & Prevention. 2005 Apr;14(4):949-57.(22)
XXIII. Powell IJ, Carpten J, Dunston G, Kittles R, Bennett J, Hoke G, Pettaway C, Weinrich S, Vijayakumar S, Ahaghotu CA, Boykin W. African-American heredity prostate cancer study: a model for genetic research. Journal of the National Medical Association. 2001 Apr;93(4):120. (23)
XXIV. Rökman A, Ikonen T, Mononen N, Autio V, Matikainen MP, Koivisto PA, Tammela TL, Kallioniemi OP, Schleutker J. ELAC2/HPC2 involvement in hereditary and sporadic prostate cancer. Cancer research. 2001 Aug 15;61(16):6038-4. (24)
XXV. Izmirli M, Arikan B, Bayazit Y, Alptekin DA. Polymorphisms of HPC2/ELAC2 and SRD5A2 (5α-reductase type II) genes in prostate cancer. Balkan Journal of Medical Genetics. 2011 Jan 1;14(1):31-5.(25)
XXVI. Djomkam AL, Beyeme Sala T, Baari Memba C, Njimoh DL. Prevalence of the Ser217Leu variant of the ELAC2 gene and its association with prostate cancer in population of the Littoral region of Cameroon. Prostate Cancer. 2019 Jun 19; 2019. (26)
XXVII. Miller DC, Zheng SL, Dunn RL, Sarma AV, Montie JE, Lange EM, Meyers DA, Xu J, Cooney KA. Germ-line mutations of the macrophage scavenger receptor 1 gene: association with prostate cancer risk in African-American men. Cancer Research. 2003 Jul 1;63(13):3486-9.(27)
XXVIII. Xu J, Zheng SL, Komiya A, Mychaleckyj JC, Isaacs SD, Chang B, Turner AR, Ewing CM, Wiley KE, Hawkins GA, Bleecker ER. Common sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. The American Journal of Human Genetics. 2003 Jan 1;72(1):208-12. (28)
XXIX. Xu, J., Zheng, S., Komiya, A. et al. Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet 32, 321–325 (2002). https://doi.org/10.1038/ng994 (29)
XXX. Hernandez W, Grenade C, Santos ER, Bonilla C, Ahaghotu C, Kittles RA. IGF-1 and IGFBP-3 gene variants influence on serum levels and prostate cancer risk in African-Americans. Carcinogenesis. 2007 Oct 1;28(10):2154-9. (30)
XXXI. Makridakis NM, Ross RK, Pike MC, Crocitto LE, Kolonel LN, Pearce CL, Henderson BE, Reichardt JK. Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. The Lancet. 1999 Sep 18;354(9183):975-8. (31)
XXXII. McDonald, A., Bunker, C., Raman, J., Richie, J., & Patrick, A. (2017). Serum carotenoid and retinol levels in African-Caribbean Tobagonian men with high prostate cancer risk in comparison with African-American men. British Journal of Nutrition, 117(8), 1128-1136. doi:10.1017/S0007114517000873 (32)
XXXIII. Giovannucci E, Ascherio A, Rimm EB, Stampfer MJ, Colditz GA, Willett WC. Intake of carotenoids and retino in relation to risk of prostate cancer. JNCI Journal of the National Cancer Institute. 1995 Dec 6;87(23):1767-76.(33)
XXXIV. Gann PH, Ma J, Giovannucci E, Willett W, Sacks FM, Hennekens CH, Stampfer MJ. Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. Cancer research. 1999 Mar 15;59(6):1225-30.(34)
XXXV. Nelson SM, Batai K, Ahaghotu C, Agurs-Collins T, Kittles RA. Association between serum 25-hydroxy-vitamin D and aggressive prostate cancer in African American men. Nutrients. 2016 Dec 28;9(1):12. (35)
XXXVI. Batai K, Murphy AB, Nonn L, Kittles RA. Vitamin D and immune response: implications for prostate cancer in African Americans. Frontiers in immunology. 2016 Feb 22;7:53. 36
XXXVII. Paller CJ, Kanaan YM, Beyene DA, Naab TJ, Copeland RL, Tsai HL, Kanarek NF, Hudson TS. Risk of prostate cancer in African‐American men: Evidence of mixed effects of dietary quercetin by serum vitamin D status. The Prostate. 2015 Sep;75(13):1376-83. 37
XXXVIII. Hollis BW, Marshall DT, Savage SJ, Garrett-Mayer E, Kindy MS, Gattoni-Celli S. Vitamin D3 supplementation, low-risk prostate cancer, and health disparities. The Journal of steroid biochemistry and molecular biology. 2013 Jul 1;136:233-7. 38
XXXIX. Ries LAG, Elsner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, et al (eds). SEER Cancer Statistics Review, 1975–2001. Available at: http://seer.cancer.gov/csr/1975_2001/ , 2004. [Last accessed: December 2, 2004.]39
XL. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med2003; 347: 215 –24.(40)
XLI. El-Bayoumy K. The role of selenium in cancer prevention. In: DeVita VT Jr, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 4th ed. Philadelpha (PA): Lippincott; 1991 . p. 1 –15. (41)
XLII. Combs GF, Combs SB. The nutritional biochemistry of selenium. Annu Rev Nutr1984 ; 4: 257 –80. (42)
XLIII. Shrauzer GN. Selenomethionine: a review of its nutritional significance, metabolism and toxicity. J Nutr2000; 130: 1653 –6.(43)
XLIV. Institute of Medicine. Panel on Dietary Antioxidants and Related Compounds. Dietary reference intakes for vitamin C, vitamin E, selenium, and carotenoids.Washington (DC): National Academy Press, 2000 .44
XLV. Clark LC, Combs GF Jr, Turnbull BW, Slate EH, Chalker DK, Chow J, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA1996; 276 : 1957 –63.45
XLVI. Duffield-Lillico AJ, Slate EH, Reid ME, Turnbull BW, Wilkins PA, Combs GF Jr, et al. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. J Natl Cancer Inst2003 ; 95 : 1477–81. (46)
XLVII. Pappas AM. Vitamin E: tocopherols and tocotrienols. In: Pappas AM, editor. Antioxidant status, diet, nutrition, and health. Boca Raton (FL): CRC; 1998 .(47)
XLVIII. Brigelius-Flohe R, Traber MG. Vitamin E: function and metabolism. FASEB J1999; 13 : 1145 –55.(48)
XLIX. Institute of Medicine. Panel on Dietary Antioxidants and Related Compounds. Dietary reference intakes for vitamin C, vitamin E, selenium, and carotenoids. Washington (DC): National Academy Press, 2000 .(49)
L. The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in males smokers. N Engl J Med1994; 330: 1029 –35.(50)
LI. Hartman TJ, Albanes D, Pietinen P, Hartman AM, Rautalahti M, Tangrea JA, et al. The association between baseline vitamin E, selenium, and prostate cancer in the alpha-tocopherol, beta-carotene cancer prevention study. Cancer Epidemiol Biomarkers Preva1998 ; 7 : 335 –40.(51)
LII. Blot WJ, Li JY, Taylor PR, Guo W, Dawsey S, Wang GQ, et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst1993 ; 85 : 1483 –92.(52)
LIII. Taylor PR, Qiao YL, Abnet CC, Dawsey SM, Yang CS, Gunter EW, et al. Prospective study of serum vitamin E levels and esophageal and gastric cancers. J Natl Cancer Inst2003 ; 95 : 1414 –6. (53)
LIV. Combs GF Jr, Scott ML. Nutritional interrelationships of vitamin E and selenium. BioScience1977 ; 27 : 467 –73.(54)
LV. Horvath PM, Ip C. Synergistic effect of vitamin E and selenium in the chemoprevention of mammary carcinogenesis in rats. Cancer Res198; 43 : 5335 –41.(55)
LVI. Apte SA, Cavazos DA, Whelan KA, Degraffenried LA. A low dietary ratio of omega-6 to omega-3 Fatty acids may delay progression of prostate cancer. Nutrition and cancer. 2013 May 1;65(4):556-62. (56)
LVII. Baade PD, Youlden DR, and Krnjacki LJ: International epidemiology of prostate cancer: Geographical distribution and secular trends. Mol Nutr Food Res 53, 171–184, 2009.(57)
LVIII. Marugame T and Katanoda K: International comparisons of cumulative risk of breast and prostate cancer, from cancer incidence in five continents: Vol. 8. Jpn J Clin Oncol 36, 399–400, 2006. (58)
LIX. Rodriguez C, McCullough ML, Mondul AM, Jacobs EJ, Chao A, et al.: Meat consumption among black and white men and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev 15, 211–216, 2006. (59)
LX. Walker M, Aronson KJ, King W, Wilson WJL, Fan W, et al.: Dietary patterns and risk of prostate cancer in Ontario, Canada. Int J Cancer 116, 592–598, 2005.(60)
LXI. Ritch CR, Wan RL, Stephens LB, Taxy JB, Huo D, et al.: Dietary fatty acids correlate with prostate cancer biopsy grade and volume in Jamaican men. J Urol 177, 97–101, 2007. (61)
LXII. Simopoulos AP: The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases. Exp Biol Med 233, 674–688, 2008.(62)
LXIII. Simopoulos AP: Evolutionary aspects of diet, the omega-6/omega-3 ratio and genetic variation: nutritional implications for chronic diseases. Biomed Pharmacother 60, 502–507, 2006. (63)
LXIV. Hsing AW, Tsao L, and Devesa SS: International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 85, 60–67, 2000.(64)
LXV. Leitzmann MF, Stampfer MJ, Michaud DS, Augustsson K, Colditz GA, et al.: Dietary intake of omega-3 and omega-6 fatty acids and the risk of prostate cancer. Am J Clin Nutr 80, 204–216. 2004.(65)
LXVI. Szymanski KM, Wheeler DC, and Mucci LA: Fish consumption and prostate cancer risk: a review and meta-analysis. Am J Clin Nutr 92, 1223–1233, 2010. (66)
LXVII. Chavarro JE, Stampfer MJ, Li H, Campos H, Kurth T, et al.: A prospective study of polyunsaturated fatty acid levels in blood and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 16, 1364–1370, 2007.(67)
LXVIII. Gomez SL, Le GM, Clarke CA, Glaser SL, France A, et al.: Cancer incidence patterns in Koreans in the US and in Kangwha, South Korea. Cancer Causes Control 14, 167–174, 2003.(68)
LXIX. Shimizu H, Ross RK, Bernstein L, Yatani R, Henderson BE, and Mack TM: Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer 63, 963–966, 1991.(69)
LXX. Lee J, Demissie K, Lu S-E, and Rhoads GG: Cancer incidence among Korean-American immigrants in the United States and native Koreans in South Korea. Cancer Control 14, 78–85, 2007.(70)
LXXI. Mamalakis G, Kafatos A, Kalogeropoulos N, Andrikopoulos N, Daskalopulos G, et al.: Prostate cancer vs hyperplasia: relationships with prostatic and adipose tissue fatty acid composition. Prostaglandins Leukot Essent Fatty Acids 66, 467–477, 2002. (71)
LXXII. Yang YJ, Lee SH, Hong SJ, and Chung BC: Comparison of fatty acid profiles in the serum of patients with prostate cancer and benign prostatic hyperplasia. Clin Biochem 32, 405–409, 1999